{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:45:03Z","timestamp":1775803503863,"version":"3.50.1"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_rir-2026-0016_s_006\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of Xeligekimab (GR1501), a fully human monoclonal antibody against interleukin-17A, in Chinese patients with active axial spondyloarthritis (axSpA) who did not respond or were intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_rir-2026-0016_s_007\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase II, randomized, double-blind, placebo-controlled, multicenter study enrolled 160 patients with active axSpA. Participants were randomized equally to receive placebo or Xeligekimab at 100 mg, 200 mg, or 300 mg subcutaneously every two weeks for 16 weeks, followed by an 8-week follow-up. The primary endpoint was the Assessment of SpondyloArthritis International Society 20 (ASAS20) response at week 16. Secondary endpoints included ASAS40, ASDAS-CRP, BASDAI, BASFI, and patient-reported outcomes. Safety and immunogenicity were evaluated throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_rir-2026-0016_s_008\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 16, ASAS20 response rates were 52.5% with placebo and 77.5%, 75.0%, and 72.5% with Xeligekimab 100 mg, 200 mg, and 300 mg, respectively. The 100 mg and 200 mg groups showed significant improvement versus placebo (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Benefits in ASAS40, ASDAS-CRP, and BASDAI were maintained through week 24. Xeligekimab was generally well tolerated, and the overall incidence of adverse events was comparable to placebo. No treatment-emergent anti-drug antibodies were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_rir-2026-0016_s_009\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Xeligekimab at 100 mg and 200 mg achieved meaningful clinical improvement with good tolerability in patients with active axSpA, supporting further clinical evaluation of this therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/rir-2026-0016","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:16:10Z","timestamp":1774876570000},"page":"41-50","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial"],"prefix":"10.1515","volume":"7","author":[{"given":"Xiaofeng","family":"Zeng","sequence":"first","affiliation":[{"name":"Rheumatology and Immunology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangzhu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Qilu Hospital of Shandong University , Jinan , Shandong Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xuanwu Hospital, Capital Medical University , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Anhui Provincial Hospital , Hefei , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Hospital of Jilin University , Changchun , Jilin Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Huashan Hospital, Fudan University , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Huashan Hospital, Fudan University , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School , Nanjing , Jiangsu Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College , Bengbu , Anhui Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Pingxiang People\u2019s Hospital , Pingxiang , Jiangxi Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hebei Petro China Central Hospital , Langfang , Hebei Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0941-2624","authenticated-orcid":false,"given":"Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026041005450744269_j_rir-2026-0016_ref_001","doi-asserted-by":"crossref","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73\u201384.","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2026041005450744269_j_rir-2026-0016_ref_002","doi-asserted-by":"crossref","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19\u201334.","DOI":"10.1136\/ard-2023-223937"},{"key":"2026041005450744269_j_rir-2026-0016_ref_003","doi-asserted-by":"crossref","unstructured":"Bittar M, Deodhar A. Axial Spondyloarthritis: A Review. JAMA. 2025;333:408\u2013420.","DOI":"10.1001\/jama.2024.20917"},{"key":"2026041005450744269_j_rir-2026-0016_ref_004","doi-asserted-by":"crossref","unstructured":"Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650\u2013657.","DOI":"10.1093\/rheumatology\/ket387"},{"key":"2026041005450744269_j_rir-2026-0016_ref_005","doi-asserted-by":"crossref","unstructured":"Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis--insights into pathogenesis. Nat Rev Rheumatol. 2016;12:81\u201391.","DOI":"10.1038\/nrrheum.2015.133"},{"key":"2026041005450744269_j_rir-2026-0016_ref_006","doi-asserted-by":"crossref","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285\u20131299.","DOI":"10.1002\/acr.24025"},{"key":"2026041005450744269_j_rir-2026-0016_ref_007","doi-asserted-by":"crossref","unstructured":"Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;2015:CD005468.","DOI":"10.1002\/14651858.CD005468.pub2"},{"key":"2026041005450744269_j_rir-2026-0016_ref_008","doi-asserted-by":"crossref","unstructured":"Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal Anti-inflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016;43:607\u2013617.","DOI":"10.3899\/jrheum.150721"},{"key":"2026041005450744269_j_rir-2026-0016_ref_009","doi-asserted-by":"crossref","unstructured":"Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187\u20131193.","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"2026041005450744269_j_rir-2026-0016_ref_010","doi-asserted-by":"crossref","unstructured":"Kroon F, Landew\u00e9 R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623\u20131629.","DOI":"10.1136\/annrheumdis-2012-201370"},{"key":"2026041005450744269_j_rir-2026-0016_ref_011","unstructured":"McGonagle DG, McInnes IB, Kirkham B, Sherlock J, Emery P. Biologic therapies in axial spondyloarthritis. Nat Rev Rheumatol. 2021;17:35\u201348."},{"key":"2026041005450744269_j_rir-2026-0016_ref_012","doi-asserted-by":"crossref","unstructured":"Lee TH, Koo BS, Nam B, et al. Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset. Ther Adv Musculoskelet Dis. 2020;12:1759720.","DOI":"10.1177\/1759720X20975912"},{"key":"2026041005450744269_j_rir-2026-0016_ref_013","doi-asserted-by":"crossref","unstructured":"Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. 2016;22:230\u2013241.","DOI":"10.1016\/j.molmed.2016.01.001"},{"key":"2026041005450744269_j_rir-2026-0016_ref_014","doi-asserted-by":"crossref","unstructured":"Blair HA. Xeligekimab: First Approval. Drugs. 2025;85:97\u2013101.","DOI":"10.1007\/s40265-024-02125-1"},{"key":"2026041005450744269_j_rir-2026-0016_ref_015","doi-asserted-by":"crossref","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371:326\u2013338.","DOI":"10.1056\/NEJMoa1314258"},{"key":"2026041005450744269_j_rir-2026-0016_ref_016","doi-asserted-by":"crossref","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016;375:345\u2013356.","DOI":"10.1056\/NEJMoa1512711"},{"key":"2026041005450744269_j_rir-2026-0016_ref_017","doi-asserted-by":"crossref","unstructured":"Ceribelli A, Motta F, Vecellio M, et al. Clinical Trials Supporting the Role of the IL-17\/IL-23 Axis in Axial Spondyloarthritis. Front Immunol. 2021;12:622770.","DOI":"10.3389\/fimmu.2021.622770"},{"key":"2026041005450744269_j_rir-2026-0016_ref_018","doi-asserted-by":"crossref","unstructured":"Jiang C, Du Y, Liu X, et al. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2023;190:28\u201336.","DOI":"10.1093\/bjd\/ljad315"},{"key":"2026041005450744269_j_rir-2026-0016_ref_019","doi-asserted-by":"crossref","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373:2534\u20132548.","DOI":"10.1056\/NEJMoa1505066"},{"key":"2026041005450744269_j_rir-2026-0016_ref_020","doi-asserted-by":"crossref","unstructured":"McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78:1167\u20131178.","DOI":"10.1136\/annrheumdis-2019-215356"},{"key":"2026041005450744269_j_rir-2026-0016_ref_021","doi-asserted-by":"crossref","unstructured":"Harrison SR, Marzo-Ortega H. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. Expert Rev Clin Immunol. 2021;17:1059\u20131071.","DOI":"10.1080\/1744666X.2021.1970534"},{"key":"2026041005450744269_j_rir-2026-0016_ref_022","doi-asserted-by":"crossref","unstructured":"Deodhar AA, Dougados M, Baeten DL, et al. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Arthritis Rheumatol. 2016;68:2901\u20132910.","DOI":"10.1002\/art.39805"},{"key":"2026041005450744269_j_rir-2026-0016_ref_023","doi-asserted-by":"crossref","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2019;71:599\u2013611.","DOI":"10.1002\/art.40753"},{"key":"2026041005450744269_j_rir-2026-0016_ref_024","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u2013991.","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2026041005450744269_j_rir-2026-0016_ref_025","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V):16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441\u20132451.","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2026041005450744269_j_rir-2026-0016_ref_026","doi-asserted-by":"crossref","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395:53\u201364.","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"2026041005450744269_j_rir-2026-0016_ref_027","doi-asserted-by":"crossref","unstructured":"Seo MR, Yeo J, Park JW, et al. Korean treatment recommendations for patients with axial spondyloarthritis. Korean J Intern Med. 2024;39:200.","DOI":"10.3904\/kjim.2023.194.e1"},{"key":"2026041005450744269_j_rir-2026-0016_ref_028","doi-asserted-by":"crossref","unstructured":"J Sieper, M Rudwaleit, X Baraliakos, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. ;:68 Suppl 2:ii1\u201344.","DOI":"10.1136\/ard.2008.104018"},{"key":"2026041005450744269_j_rir-2026-0016_ref_029","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Medina C, Molto A, Sepriano A, et al. Sensitivity to change of structural outcomes in axial spondyloarthritis after 10 years of follow up. Data from the DESIR cohort. RMD Open. 2024;10:e004400.","DOI":"10.1136\/rmdopen-2024-004400"},{"key":"2026041005450744269_j_rir-2026-0016_ref_030","doi-asserted-by":"crossref","unstructured":"Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis--insights into pathogenesis. Nat Rev Rheumatol. 2016;12:81\u201391.","DOI":"10.1038\/nrrheum.2015.133"},{"key":"2026041005450744269_j_rir-2026-0016_ref_031","doi-asserted-by":"crossref","unstructured":"Robinson PC, Leo PJ, Pointon JJ, et al. Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease. NPJ Genom Med. 2016;1:16008.","DOI":"10.1038\/npjgenmed.2016.8"}],"container-title":["Rheumatology and Immunology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/rir-2026-0016\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/rir-2026-0016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:45:41Z","timestamp":1775799941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/rir-2026-0016\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,4,8]]}},"alternative-id":["10.1515\/rir-2026-0016"],"URL":"https:\/\/doi.org\/10.1515\/rir-2026-0016","relation":{},"ISSN":["2719-4523"],"issn-type":[{"value":"2719-4523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}